Product ID: SQMIG35H2218
Global Gene Therapy Market Size, Share, Growth Analysis, By Vector(Lentivirus, AAV), By Indication(Acute Lymphoblastic Leukemia (ALL), Inherited Retinal Disease) - Industry Forecast 2024-2031
Report ID:
SQMIG35H2218 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
73 |
Figures:
75
Global Gene Therapy Market Regional Insights
In 2022, North America emerged as the dominant region in the gene therapy market, contributing to over 65.0% of the overall revenue. It is projected to remain the largest routine manufacturer of gene therapy drugs during the forecast period, with increasing investments in R&D by companies of all sizes. The market is being driven by rising government investments and the growing prevalence of targeted diseases in the region, such as spinal muscular atrophy, affecting 10,000 to 25,000 individuals in the U.S. alone, according to the Spinal Muscular Atrophy Foundation.
Asia Pacific is expected to be the fastest-growing regional segment from 2023 to 2030, owing to its large population with unmet medical needs and the growing demand for innovative technologies to treat rare but increasingly prevalent diseases. The commercial application of genetic therapies is likely to witness significant growth in this region due to the availability of resources, the presence of major companies, and government investments.
Global Gene Therapy Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
